PDF factsheet
      Z

HER2 inhibitors in early breast cancer for HER2 positive patients, clinical trials results

pertuzumab versus placebo
Aphinity,
NCT01358877

versus
people with operable HER2-positive eBCdouble-blind
trastuzumab versus control
NSABP B31, 2005
52 weeks of trastuzumab
versus
no trastuzumab
patients with node-positive, HER2-positive breast cancer
BCIRG006, 2013

versus
Buzdar, 2005
simultaneous weekly trastuzumab for 24 weeks
versus
no trastuzumab
patienst with HER 2-positive operable breast cancer
FinHer, 2006
concomitant treatment with trastuzumab
versus
no trastuzumab
Women with tumors that overexpressed HER2/neu
HERA, 2005
???
versus
???
patients with HER2-positive and either node-negative or node-positive breast cancer who had completed locoregional therapy and at least four cycles of neoadjuvant or adjuvant chemotherapy
N9831, 2005

versus
NOAH, 2010
1 year of treatment with trastuzumab (given as neoadjuvant and adjuvant treatment
versus
no trastuzumab
patients with HER2-positive locally advanced breast cancer
PACS-04, 2009

versus
N9831 (1), 0

versus
N9831 (2), 0

versus
FinHer (1), 3000

versus

  Options


in first

in second

  Filter